164 related articles for article (PubMed ID: 37921547)
1. Mechanism of synergistic inhibitory effect of benzyl isothiocyanate and zoledronic acid combination on breast cancer induction of osteoclast differentiation.
Hahm ER; Kim SH; Pore SK; Mathan SV; Singh RP; Singh SV
Mol Carcinog; 2024 Feb; 63(2):301-313. PubMed ID: 37921547
[TBL] [Abstract][Full Text] [Related]
2. Prevention of breast cancer-induced osteolytic bone resorption by benzyl isothiocyanate.
Pore SK; Hahm ER; Latoche JD; Anderson CJ; Shuai Y; Singh SV
Carcinogenesis; 2018 Feb; 39(2):134-145. PubMed ID: 29040431
[TBL] [Abstract][Full Text] [Related]
3. Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review.
Wang L; Fang D; Xu J; Luo R
BMC Cancer; 2020 Nov; 20(1):1059. PubMed ID: 33143662
[TBL] [Abstract][Full Text] [Related]
4. Withaferin A inhibits breast cancer-induced osteoclast differentiation.
Hahm ER; Kim SH; Singh SV
Mol Carcinog; 2023 Jul; 62(7):1051-1061. PubMed ID: 37067392
[TBL] [Abstract][Full Text] [Related]
5. In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
Shibuya I; Takami M; Miyamoto A; Karakawa A; Dezawa A; Nakamura S; Kamijo R
Pathol Oncol Res; 2019 Jan; 25(1):409-419. PubMed ID: 29159783
[TBL] [Abstract][Full Text] [Related]
6. Benzyl isothiocyanate inhibits oncogenic actions of leptin in human breast cancer cells by suppressing activation of signal transducer and activator of transcription 3.
Kim SH; Nagalingam A; Saxena NK; Singh SV; Sharma D
Carcinogenesis; 2011 Mar; 32(3):359-67. PubMed ID: 21163886
[TBL] [Abstract][Full Text] [Related]
7. Structural simulation of adenosine phosphate via plumbagin and zoledronic acid competitively targets JNK/Erk to synergistically attenuate osteoclastogenesis in a breast cancer model.
Qiao H; Wang TY; Yu ZF; Han XG; Liu XQ; Wang YG; Fan QM; Qin A; Tang TT
Cell Death Dis; 2016 Feb; 7(2):e2094. PubMed ID: 26866274
[TBL] [Abstract][Full Text] [Related]
8. Suppression of FOXQ1 in benzyl isothiocyanate-mediated inhibition of epithelial-mesenchymal transition in human breast cancer cells.
Sehrawat A; Kim SH; Vogt A; Singh SV
Carcinogenesis; 2013 Apr; 34(4):864-73. PubMed ID: 23276794
[TBL] [Abstract][Full Text] [Related]
9. Benzyl isothiocyanate inhibits epithelial-mesenchymal transition in cultured and xenografted human breast cancer cells.
Sehrawat A; Singh SV
Cancer Prev Res (Phila); 2011 Jul; 4(7):1107-17. PubMed ID: 21464039
[TBL] [Abstract][Full Text] [Related]
10. Notch2 activation by benzyl isothiocyanate impedes its inhibitory effect on breast cancer cell migration.
Kim SH; Sehrawat A; Singh SV
Breast Cancer Res Treat; 2012 Aug; 134(3):1067-79. PubMed ID: 22476855
[TBL] [Abstract][Full Text] [Related]
11. Benzyl isothiocyanate causes FoxO1-mediated autophagic death in human breast cancer cells.
Xiao D; Bommareddy A; Kim SH; Sehrawat A; Hahm ER; Singh SV
PLoS One; 2012; 7(3):e32597. PubMed ID: 22457718
[TBL] [Abstract][Full Text] [Related]
12. Molecular and cellular mechanisms for zoledronic acid-loaded magnesium-strontium alloys to inhibit giant cell tumors of bone.
Li M; Wang W; Zhu Y; Lu Y; Wan P; Yang K; Zhang Y; Mao C
Acta Biomater; 2018 Sep; 77():365-379. PubMed ID: 30030174
[TBL] [Abstract][Full Text] [Related]
13. CSF-1 blockade impairs breast cancer osteoclastogenic potential in co-culture systems.
Liverani C; Mercatali L; Spadazzi C; La Manna F; De Vita A; Riva N; Calpona S; Ricci M; Bongiovanni A; Gunelli E; Zanoni M; Fabbri F; Zoli W; Amadori D; Ibrahim T
Bone; 2014 Sep; 66():214-22. PubMed ID: 24956020
[TBL] [Abstract][Full Text] [Related]
14. Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid In vitro.
Qiao H; Wang TY; Yan W; Qin A; Fan QM; Han XG; Wang YG; Tang TT
Acta Pharmacol Sin; 2015 Sep; 36(9):1085-98. PubMed ID: 26235741
[TBL] [Abstract][Full Text] [Related]
15. p53-Independent apoptosis by benzyl isothiocyanate in human breast cancer cells is mediated by suppression of XIAP expression.
Kim SH; Singh SV
Cancer Prev Res (Phila); 2010 Jun; 3(6):718-26. PubMed ID: 20484174
[TBL] [Abstract][Full Text] [Related]
16. Role of Krüppel-like Factor 4-p21
Kim SH; Singh SV
Cancer Prev Res (Phila); 2019 Mar; 12(3):125-134. PubMed ID: 30723175
[TBL] [Abstract][Full Text] [Related]
17. Toxicities following treatment with bisphosphonates and receptor activator of nuclear factor-κB ligand inhibitors in patients with advanced prostate cancer.
Gartrell BA; Coleman RE; Fizazi K; Miller K; Saad F; Sternberg CN; Galsky MD
Eur Urol; 2014 Feb; 65(2):278-86. PubMed ID: 23706567
[TBL] [Abstract][Full Text] [Related]
18. Modulating Bone Marrow Hematopoietic Lineage Potential to Prevent Bone Metastasis in Breast Cancer.
Ubellacker JM; Baryawno N; Severe N; DeCristo MJ; Sceneay J; Hutchinson JN; Haider MT; Rhee CS; Qin Y; Gregory WM; Garrido-Castro AC; Holen I; Brown JE; Coleman RE; Scadden DT; McAllister SS
Cancer Res; 2018 Sep; 78(18):5300-5314. PubMed ID: 30065048
[TBL] [Abstract][Full Text] [Related]
19. Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis.
Liu L; Geng H; Mei C; Chen L
Oxid Med Cell Longev; 2021; 2021():6661534. PubMed ID: 33859780
[TBL] [Abstract][Full Text] [Related]
20. Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody.
von Moos R; Costa L; Gonzalez-Suarez E; Terpos E; Niepel D; Body JJ
Cancer Treat Rev; 2019 Jun; 76():57-67. PubMed ID: 31136850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
